Allergic Rhinitis Drugs Market Forecast 2014-2024

Allergic Rhinitis Drugs Market Forecast 2014-2024

Future Prospects for Companies in Antihistamines, Corticosteroids, Immunotherapy & Vaccines

©noticeThis material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.

www.visiongain.com

Contents

1. Report Overview

1.1 Global Allergic Rhinitis Drugs Market Overview

1.2 Global Allergic Rhinitis Drugs Market Segmentation

1.3 Why You Should Read This Report

1.4 How This Report Delivers

1.5 Key Questions Answered by This Analytical Report

1.6 Who is This Report For?

1.7 Methodology

1.8 Frequently Asked Questions (FAQ)

1.9 Associated Visiongain Reports

1.10 About Visiongain

2. Introduction to Allergic Rhinitis

2.1 The Pharmaceutical Industry: a Very Brief Overview

2.2 A Brief Overview of Allergy

2.3 Allergic Rhinitis

2.3.1 The Global Prevalence of Allergic Rhinitis

2.3.2 Pathophysiology of Allergic Rhinitis: IgEs and Mast Cells

2.3.3 Symptoms of Allergic Rhinitis

2.3.4 Classification of Allergic Rhinitis

2.3.4.1 Non-Allergic Rhinitis and Mixed Rhinitis

2.3.5 Seasonal Allergic Rhinitis (Hay Fever)

2.3.6 Perennial Allergic Rhinitis

1. Report Overview

2. Introduction to Allergic Rhinitis

www.visiongain.com

Contents

2.3.7 Diagnosis of Allergic Rhinitis

2.4 Treatment of Allergic Rhinitis

2.4.1 Antihistamines

2.4.1.1 First-Generation Antihistamines

2.4.1.2 Second- and Third-Generation Antihistamines

2.4.2 Corticosteroids

2.4.2.1 First-, Second- and Third-Generation Intranasal Corticosteroids

2.4.2.2 Combination Drug Products

2.4.3 Leukotriene Receptor Antagonists

2.4.4 Cromolyn (cromoglicic acid)

2.4.5 Decongestants

2.4.6 Saline Nasal Sprays

2.4.7 Immunotherapy and Vaccines

2.5 Phases of Clinical Trials

2.6 Scope of this Report

2.7 Currency Exchange Rates in This Report

3. Allergic Rhinitis Drugs: World Market 2014-2024

3.1 The World Allergic Rhinitis Drugs Market in 2013

3.1.1 Leading Allergic Rhinitis Drugs

3.1.2 Leading Companies in the Allergic Rhinitis Drugs Market

3.2 World Allergic Rhinitis Drugs Market: Sales Forecast 2014-2024

3.3 Oral Antihistamines Lead the World Allergic Rhinitis Drugs Market

3.4 How Will Segmental Market Shares Change to 2024?

3. Allergic Rhinitis Drugs: World Market 2014-2024

www.visiongain.com

Contents

3.5 World Allergic Rhinitis Drugs Market: Drivers and Restraints 2014-2024

4. Leading National Markets 2014-2024

4.1 Geographical Breakdown of the World Allergic Rhinitis Drugs Market

4.2 World Allergic Rhinitis Drugs Market: National Markets Forecast 2014-2024

4.2.1 How Will National Market Shares Change to 2024?

4.3 The US Allergic Rhinitis Drugs Market 2014-2024

4.3.1 US Allergic Rhinitis Drugs Market Forecast 2014-2024

4.3.2 US Allergic Rhinitis Drugs Market: Trends and Developments

4.3.2.1 Rx-to-OTC Switching of Intranasal Corticosteroids

4.3.2.2 Affordable Care Act: Expanding Medicare Coverage

4.4 Chinese Allergic Rhinitis Drugs Market 2014-2024

4.4.1 Chinese Allergic Rhinitis Drugs Market Forecast 2014-2024

4.4.2 Chinese Allergic Rhinitis Drugs Market: Trends and Developments

4.4.2.1 Air Pollution Associated With Increasing Prevalence

4.4.2.2 Expansion of Healthcare Coverage and Reimbursement

4.5 Japanese Allergic Rhinitis Drugs Market 2014-2024

4.5.1 Japanese Allergic Rhinitis Drugs Market Forecast 2014-2024

4.5.2 Japanese Allergic Rhinitis Drugs Market: Trends and Developments

4.5.2.1 Cedar Reforestation and the Hay Fever Epidemic

4.5.2.2 Generic Penetration to Reach 60% by 2018?

4.5.2.3 Genetically Modified Rice as Immunotherapy

4.6 EU5 Allergic Rhinitis Drugs Market 2014-2024

4.6.1 German Allergic Rhinitis Drugs Market Forecast 2014-2024

4. Leading National Allergic Rhinitis Drugs Markets 2014-2024

www.visiongain.com

Contents

4.6.2 French Allergic Rhinitis Drugs Market Forecast 2014-2024

4.6.3 UK Allergic Rhinitis Drugs Market Forecast 2014-2024

4.6.4 Italian Allergic Rhinitis Drugs Market Forecast 2014-2024

4.6.5 Spanish Allergic Rhinitis Drugs Market Forecast 2014-2024

4.6.6 EU5 Allergic Rhinitis Drugs Market: Trends and Developments

4.6.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law

4.6.6.2 France: Social Security Finance Bill 2014

4.6.6.3 UK: Increasing Burden of Allergy

4.6.6.4 Italy: Austerity Measures Limiting Growth

4.6.6.5 Spain: The Start of Recovery in the Spanish Economy

4.7 Russian Allergic Rhinitis Drugs Market 2014-2024

4.7.1 Russian Allergic Rhinitis Drugs Market Forecast 2014-2024

4.7.2 Russian Allergic Rhinitis Drugs Market: Trends and Developments

4.7.2.1 Pharma2020 and the Russian Pharmaceutical Industry

4.8 Indian Allergic Rhinitis Drugs Market 2014-2024

4.8.1 Indian Allergic Rhinitis Drugs Market Forecast 2014-2024

4.8.2 Indian Allergic Rhinitis Drugs Market: Trends and Developments

4.8.2.1 Drug Prices Control Order 2013

4.8.2.2 Expansion of Healthcare Provision

4.9 Brazilian Allergic Rhinitis Drugs Market 2014-2024

4.9.1 Brazilian Allergic Rhinitis Drugs Market Forecast 2014-2024

4.9.2 Brazilian Allergic Rhinitis Drugs Market: Trends and Developments

4.9.2.1 Increasing Access to Medicines

4.10 Mexican Allergic Rhinitis Drugs Market 2014-2024

www.visiongain.com

Contents

4.10.1 Mexican Allergic Rhinitis Drugs Market Forecast 2014-2024

4.10.2 Mexican Allergic Rhinitis Drugs Market: Trends and Developments

4.10.2.1 Seguro Popular: Mexican Healthcare Reform

5. Oral Antihistamines Market 2014-2024

5.1 Oral Antihistamines: A Market in Decline

5.2 Leading Oral Antihistamines in 2013

5.3 Oral Antihistamines: Market Forecast 2014-2024

5.4 Market Share of Leading Oral Antihistamines to 2024

5.5 Oral Antihistamines: Trends and Developments

5.5.1 Patent Expiry and Generic Competition

5.5.2 The Rx-to-OTC Rush

5.5.3 Combination Therapy with Intranasal Corticosteroids

5.6 Allegra/Allegra-D/Allegra OTC (fexofenadine, Sanofi)

5.6.1 Allegra/Allegra OTC: Sales Forecast 2014-2024

5.7 Zyrtec/Zyrtec D (cetirizine, Johnson & Johnson/UCB/GSK)

5.7.1 Zyrtec/Zyrtec D: Sales Forecast 2014-2024

5.8 Claritin/Claritin OTC (loratadine, Merck & Co.)

5.8.1 Claritin/Claritin OTC: Sales Forecast 2014-2024

5.9 Xyzal (levocetirizine, Sanofi/UCB/GSK)

5.9.1 Xyzal: Sales Forecast 2014-2024

5.10 Allelock (olopatadine, Kyowa Hakko Kirin)

5.10.1 Allelock: Sales Forecast 2014-2024

5.11 Clarinex (desloratadine, Merck & Co.)

5. Oral Antihistamines Market 2014-2024

www.visiongain.com

Contents

5.11.1 Clarinex: Sales Forecast 2014-2024

5.12 Talion (bepotastine, Mitsubishi Tanabe)

5.12.1 Talion: Sales Forecast 2014-2024

5.13 Ebastel (ebastine, Almirall/Takeda/Dainippon Sumitomo)

5.13.1 Ebastel: Sales Forecast 2014-2024

5.14 Other Oral Antihistamines

6. Intranasal Corticosteroids Market 2014-2024

6.1 Intranasal Corticosteroids: First-line for Allergic Rhinitis

6.2 Leading Intranasal Corticosteroids in 2013

6.3 Intranasal Corticosteroids: Market Forecast by Value, 2014-2024

6.4 Intranasal Corticosteroids: Market Forecast by Volume, 2014-2024

6.5 Market Share of Leading Intranasal Corticosteroids to 2024

6.6 Intranasal Corticosteroids: Trends and Developments

6.6.1 Nasonex Patent Expiry in 2014

6.6.2 Nasacort AQ Switched to OTC

6.7 Nasonex (mometasone, Merck)

6.7.1 Nasonex: Sales Forecast by Value, 2014-2024)

6.7.2 Nasonex: Sales Forecast by Volume, 2014-2024)

6.8 Avamys/Veramyst (fluticasone furoate, GSK)

6.8.1 Avamys/Veramyst: Sales Forecast by Value, 2014-2024)

6.8.2 Avamys/Veramyst: Sales Forecast by Volume, 2014-2024)

6.9 Flixonase/Flonase (fluticasone propionate, GSK)

6.9.1 Flixonase/Flonase: Sales Forecast by Value, 2014-2024)

6. Intranasal Corticosteroids Market 2014-2024

www.visiongain.com

Contents

6.9.2 Flixonase/Flonase: Sales Forecast by Volume, 2014-2024)

6.10 Rhinocort (budesonide, AstraZeneca)

6.10.1 Rhinocort: Sales Forecast by Value, 2014-2024)

6.10.2 Rhinocort: Sales Forecast by Volume, 2014-2024)

6.11 Omnaris (ciclesonide, Dainippon Sumitomo/Takeda)

6.11.1 Omnaris: Sales Forecast by Value, 2014-2024)

6.11.2 Omnaris: Sales Forecast by Volume, 2014-2024)

6.12 Beconase/Beconase AQ (beclometasone, GSK/Omega Pharma)

6.12.1 Beconase/Beconase AQ: Sales Forecast by Value, 2014-2024)

6.12.2 Beconase/Beconase AQ: Sales Forecast by Volume, 2014-2024)

6.13 Nasacort (triamcinolone, Sanofi)

6.13.1 Nasacort: Sales Forecast by Value, 2014-2024)

6.13.2 Nasacort: Sales Forecast by Volume, 2014-2024)

6.14 QNasl (beclometasone, Teva)

6.14.1 QNasl: Sales Forecast by Value, 2014-2024)

6.14.2 QNasl: Sales Forecast by Volume, 2014-2024)

6.15 Zetonna (ciclesonide, Dainippon Sumitomo)

6.15.1 Zetonna: Sales Forecast by Value, 2014-2024)

6.15.2 Zetonna: Sales Forecast by Volume, 2014-2024)

6.16 Generic Intranasal Corticosteroids

6.16.1 Generic Intranasal Beclometasone

6.16.1.1 Generic Intranasal Beclometasone: Sales Forecast by Value, 2014-2024

6.16.1.2 Generic Intranasal Beclometasone: Sales Forecast by Volume, 2014-2024

6.16.2 Generic Intranasal Budesonide

www.visiongain.com

Contents

6.16.2.1 Generic Intranasal Budesonide: Sales Forecast by Value, 2014-2024

6.16.2.2 Generic Intranasal Budesonide: Sales Forecast by Volume, 2014-2024

6.16.3 Generic Intranasal Flunisolide

6.16.3.1 Generic Intranasal Flunisolide: Sales Forecast by Value, 2014-2024

6.16.3.2 Generic Intranasal Flunisolide: Sales Forecast by Volume, 2014-2024

6.16.4 Generic Intranasal Fluticasone

6.16.4.1 Generic Intranasal Fluticasone: Sales Forecast by Value, 2014-2024

6.16.4.2 Generic Intranasal Fluticasone: Sales Forecast by Volume, 2014-2024

6.16.5 Generic Intranasal Mometasone

6.16.5.1 Generic Intranasal Mometasone: Sales Forecast by Value, 2014-2024

6.16.5.2 Generic Intranasal Mometasone: Sales Forecast by Volume, 2014-2024

6.16.6 Generic Intranasal Triamcinolone

6.16.6.1 Generic Intranasal Triamcinolone: Sales Forecast by Value, 2014-2024

6.16.6.2 Generic Intranasal Triamcinolone: Sales Forecast by Volume, 2014-2024

7. Intranasal Antihistamines Market 2014-2024

7.1 Intranasal Antihistamines: A Niche Segment

7.2 Leading Intranasal Antihistamines in 2013

7.3 Intranasal Antihistamines: Market Forecast by Value, 2014-2024

7.4 Intranasal Antihistamines: Market Forecast by Volume, 2014-2024

7.5 Market Share of Leading Intranasal Antihistamines to 2024

7.6 Intranasal Antihistamines: Trends and Developments

7.6.1 Azelastine versus Olopatadine

7.6.2 Intranasal Combination Products

7. Intranasal Antihistamines Market 2014-2024

www.visiongain.com

Contents

7.7 Astepro (azelastine, Meda)

7.7.1 Astepro: Sales Forecast 2014-2024

7.8 Patanase (olopatadine, Novartis)

7.8.1 Patanase: Sales Forecast 2014-2024

7.9 Astelin (azelastine, Meda)

7.9.1 Astelin: Sales Forecast 2014-2024

7.10 Dymista (azelastine/fluticasone, Meda)

7.10.1 Dymista: Sales Forecast 2014-2024

7.11 Generic Intranasal Azelastine

7.11.1 Generic Intranasal Azelastine: Sales Forecast by Value, 2014-2024

7.11.1 Generic Intranasal Azelastine: Sales Forecast by Volume, 2014-2024

7.12 Generic Intranasal Olopatadine

7.12.1 Generic Intranasal Azelastine: Sales Forecast by Value, 2014-2024

7.12.2 Generic Intranasal Azelastine: Sales Forecast by Volume, 2014-2024

8. Immunotherapy and Vaccines Market 2014-2024

8.1 Immunotherapy: Set for Rapid Expansion

8.2 Leading Immunotherapy Products in 2013

8.3 Immunotherapy: Market Forecast 2014-2024

8.4 Market Share of Leading Immunotherapy Products to 2024

8.5 Immunotherapy: Leading Companies

8.6 Immunotherapy: Trends and Developments

8.6.1 Subcutaneous and Sublingual Immunotherapy

8.6.2 Expansion into the US Market

8. Immunotherapy and Vaccines Market 2014-2024

www.visiongain.com

Contents

8.6.3 Standardisation of Immunotherapy Products

8.6.4 Immunotherapy as a Preventative Treatment

8.7 Staloral (Grass pollen allergen extract, Stallergenes)

8.7.1 Staloral: Sales Forecast 2014-2024

8.8 Alutard SQ (Grass pollen allergen extract, ALK-Abelló)

8.8.1 Alutard SQ: Sales Forecast 2014-2024

8.9 Grazax/Grastek (Timothy grass pollen allergen extract, ALK-Abelló/Merck)

8.9.1 Grazax/Grastek: Sales Forecast 2014-2024

8.10 Oralair (Grass pollen allergen extract, Stallergenes/Greer)

8.10.1 Oralair: Sales Forecast 2014-2024

8.11 Ragwitek (Short ragweed pollen allergen extract, Merck)

8.11.1 Ragwitek: Sales Forecast 2014-2024

9. Leading Companies in the Allergic Rhinitis Drugs Market

9.1 Allergic Rhinitis Drugs: Merck & Co. Leads in a Fragmented Market

9.2 ALK-Abelló

9.2.1 ALK-Abelló: Allergic Rhinitis Drugs

9.2.2 ALK-Abelló: Allergic Rhinitis Sales Forecast 2014-2024

9.2.3 ALK-Abelló: Products in Development

9.2.4 ALK-Abelló: Recent Developments

9.2.4.1 ALK Collaborates with EddingPharm to Boost China Sales

9.2.4.2 Jext Product Recall

9.3 GSK

9.3.1 GSK: Allergic Rhinitis Drugs

9. Leading Companies in the Allergic Rhinitis Drugs Market in 2014

www.visiongain.com

Contents

9.3.2 GSK: Allergic Rhinitis Sales Forecast 2014-2024

9.3.3 GSK: Products in Development

9.3.4 GSK: Recent Developments

9.3.4.1 GSK Divestment of OTC Products

9.3.4.2 GSK Asset Swap with Novartis to Restructure Consumer Health

9.4 Johnson & Johnson

9.4.1 Johnson & Johnson: Allergic Rhinitis Drugs

9.4.2 Johnson & Johnson: Allergic Rhinitis Sales Forecast 2014-2024

9.4.3 Johnson & Johnson: Recent Developments

9.4.3.1 Launch of Zyrtec Dissolve Tabs

9.4.3.2 Manufacturing Recalls at McNeil Consumer Healthcare

9.5 Kyowa Hakko Kirin

9.5.1 Kyowa Hakko Kirin: Allergic Rhinitis Drugs

9.5.2 Kyowa Hakko Kirin: Allergic Rhinitis Sales Forecast 2014-2024

9.6 Merck & Co.

9.6.1 Merck: Allergic Rhinitis Drugs

9.6.2 Merck: Allergic Rhinitis Sales Forecast 2014-2024

9.6.3 Merck: Products in Development

9.6.4 Merck: Recent Developments

9.6.4.1 Bayer Acquires Merck’s Consumer Health Business

9.6.4.2 FDA Rejects Singulair OTC Switch

9.7 Sanofi

9.7.1 Sanofi: Allergic Rhinitis Drugs

9.7.2 Sanofi: Allergic Rhinitis Sales Forecast 2014-2024

www.visiongain.com

Contents

9.8 Stallergenes

9.8.1 Stallergenes: Allergic Rhinitis Drugs

9.8.2 Stallergenes: Allergic Rhinitis Sales Forecast 2014-2024

9.8.3 Stallergenes: Products in Development

9.8.4 Stallergenes: Recent Developments

9.8.4.1 Stallergenes Acquires Argentinean Company Alergo Pharma

9.8.4.2 Greer launches Oralair in the US

9.9 UCB

9.9.1 UCB: Allergic Rhinitis Drugs

9.9.2 UCB: Allergic Rhinitis Sales Forecast 2014-2024

9.10 Other Leading Companies

10. Allergic Rhinitis Pipeline Analysis 2014-2024

10.1 Trends and Developments in the Allergic Rhinitis Pipeline

10.2 The Oral Antihistamine Pipeline 2014

10.2.1 Talion (bepotastine, Mitsubishi Tanabe)

10.2.2 ZPL-3893787 (histamine H4R antagonist, Ziarco Pharma)

10.2.3 ZPL-868087 (oral histamine H3R antagonist, Ziarco Pharma)

10.3 The Intranasal Corticosteroids Pipeline 2014

10.3.1 APC-3000 (HFA inhaled corticosteroid, Adamis Pharmaceuticals)

10.3.2 S0597 (topical glucocorticoid, Sun Pharma)

10.3.3 TBS-6 (Trimel Pharmaceuticals)

10.4 The Immunotherapy Pipeline 2014

10.4.1 Actair (house dust mite SLIT, Stallergenes/Shionogi)

10. Allergic Rhinitis Drugs Pipeline Analysis 2014-2024

www.visiongain.com

Contents

10.4.2 AllerT (subcutaneous birch pollen immunotherapy, Anergis)

10.4.3 Cat-SPIRE and other -SPIRE Therapies (synthetic peptide immunoregulatory epitopes,

Circassia)

10.4.4 Depigoid Birch 5000 (birch pollen allergen extract, Leti Pharma)

10.4.5 House Dust Mite SLIT-Tablet (MK-8237, ALK-Abelló/Merck/Torii)

10.4.6 Pollinex Quattro (subcutaneous immunotherapies, Allergy Therapeutics)

10.4.7 gp-ASIT+ (grass pollen allergen fragments, Biotech Tools)

10.4.8 Betula verrucosa (Bet v) 1 allergen (Stallergenes)

10.5 The Pipeline for Other Allergic Rhinitis Drugs 2014

10.5.1 eN-Lac (Lactobacillus paracasei GMNL-32, GenMont Biotech)

10.5.2 S-555739 (prostaglandin D2 receptor antagonist, Shionogi)

10.5.3 DSP-3025/AZD-8848 (toll-like receptor 7 agonist, Dainippon Sumitomo/AstraZeneca)

10.5.4 GSK2245035 (toll-like receptor 7 agonist, GSK)

10.5.5 HP-3060 (transdermal long-acting tape, Hisamitsu)

10.5.6 MRX-4 (anti-inflammatory agent, Celsus Therapeutics)

10.5.7 OC459 (Oxagen/Atopix Therapeutics/Eleventa)

10.5.8 ONO-4053 (prostaglandin D2 receptor antagonist, Ono Pharmaceutical)

10.5.9 WF10 (tetrachlorodecaoxygen chlorite matrix, Nuvo Research)

10.5.10 RPL554 (PDE-3/PDE-4 antagonist, Verona Pharma)

10.5.11 VTX-1463 (toll-like receptor 8 agonist, VentiRx)

11. Qualitative Analysis of the Allergic Rhinitis Drugs Market 2014-2024

11.1 SWOT Analysis of the Allergic Rhinitis Drugs Market

11. Qualitative Analysis of the Allergic Rhinitis Drugs Market 2014-

2024

www.visiongain.com

Contents

11.2 Strengths

11.2.1 High Unmet Clinical Need

11.2.2 Established Role of Allergic Rhinitis Drugs in Treatment

11.2.3 High Profile Disease Encouraging Improving Healthcare Provision

11.2.4 Increasing Consumer Demand

11.3 Weaknesses

11.3.1 Increasing Generic Penetration

11.3.2 Patient Dissatisfaction with Intranasal Corticosteroids

11.3.3 Limited Allergic Rhinitis Drugs Pipeline

11.4 Opportunities

11.4.1 The Rise of Immunotherapy

11.4.2 Higher Growth in Emerging Markets

11.4.3 Combination Drug Products

11.4.4 Rx-to-OTC Switching

11.5 Threats

11.5.1 Patent Expiry

11.5.2 Cost-Containment

11.5.3 Rising API and Manufacturing Costs

11.6 Porter’s Five Forces Analysis of the Allergic Rhinitis Drugs Market

11.6.1 Rivalry Among Competitors [High]

11.6.2 Threat of New Entrants [Low]

11.6.3 Power of Suppliers [Low]

11.6.4 Power of Buyers [Medium]

11.6.5 Threat of Substitutes [Low]

www.visiongain.com

Contents

12. Research Interviews

12.1 Interview with Maureen Jenkins, Director of Clinical Services for Allergy UK, Sidcup, Kent,

UK

12.1.1 Allergic Rhinitis in the UK

12.1.2 Allergic Rhinitis Treatments

12.1.3 Opportunities for Manufacturers

12.2 Interview with Kimihiro Okubo, Chairman and Professor, Department of Otolaryngology,

Nippon Medical School, Tokyo, Japan

12.2.1 Allergic Rhinitis in Japan

12.3 Interview with Jonathan Bernstein, Chairman and Professor, Department of Internal

Medicine, University of Cincinnati, Ohio, US

12.3.1 Allergic Rhinitis in the US

12.3.2 Nasacort AQ and OTC Nasal Sprays

12.3.3 Dymista and Combination Therapies

12.3.4 Trends and Developments in Allergic Rhinitis

12.4 Interview with Tonya Winders, President and CEO, Allergy & Asthma Network Mothers of

Asthmatics, Virginia, US



12.4.3 US Healthcare Reform and Intranasal Drugs

12.5 Interview with Allergy Medical UK, Weybridge, UK


12. Research Interviews

www.visiongain.com

Contents

13. Conclusions

13.1 Allergic Rhinitis Drugs: A Mature Market

13.2 The World Allergic Rhinitis Market in 2013

13.2.1 Current Leading Allergic Rhinitis Segments

13.2.2 Leading Allergic Rhinitis Products

13.2.3 Leading Allergic Rhinitis Drugs Companies

13.2.4 Leading National Markets

13.3 World Allergic Rhinitis Drugs Market Forecast 2014-2024

13.4 Allergic Rhinitis Late-Stage Pipeline 2014

13.5 The Future of the Allergic Rhinitis Drugs Market?

13. Conclusions

www.visiongain.com Page 99

Allergic Rhinitis Drugs Market Forecast 2014-2024: Future Prospects for Companies in Antihistamines, Corticosteroids, Immunotherapy & Vaccines

ISAAC epidemiological study of allergic rhinitis, Argentina, Brazil and Mexico had allergic rhinitis

prevalences in 13-14 year olds (around 2002-2003) of 16.9%, 15.8% and 7.1% respectively.

Another epidemiological study called Allergies in Latin America was conducted in February-April

2008 and reported that 67% of allergic rhinitis sufferers were using medication for their condition.

24% reported using a prescription nasal spray in the past four weeks while 42% also reported

using OTC medication. Prescription nasal spray use was higher in Mexico (26%) and Argentina

(21%) than in Brazil (19%). The opposite pattern was seen in terms of patients not being treated at

all, with 43% not being treated in Brazil compared to 34% in Argentina and 28% in Mexico. Other

countries with higher use of prescription nasal sprays were Venezuela (49%), Colombia (33%) and

Chile (27%). The use of prescription nasal sprays was influenced by effectiveness, medical

opinion, patient choice, side-effects and cost. These findings suggest that there is further room for

expansion in the Brazilian and Mexican markets.

4.9.1 Brazilian Allergic Rhinitis Drugs Market Forecast 2014-2024

Table 4.15 and Figure 4.16 show visiongain’s forecast for the Brazilian allergic rhinitis drugs

market over 2013-2024.

Visiongain estimates that in 2013, the Brazilian allergic rhinitis drugs market reached $202m,

representing 1.8% of the world market. In 2014 the Brazilian market will increase to $227m, up

12.3% on 2013. High growth in this market is expected as the demand for allergic rhinitis drugs

increases. Expansion of healthcare provision in Brazil and strong economic growth will drive

demand. Visiongain predicts that the Brazilian market will grow with a CAGR of 12.4% over 2013-

2018 to reach $363m in 2018. The Brazilian market will grow at a CAGR of 11.7% over 2018-2024

to reach $705m in 2024, representing an overall CAGR of 12.0% over 2013-2024.

Table 4.15 Brazilian Allergic Rhinitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024Brazil ($m) 202 227 255 289 323 363 409 466 526 589 655 705Annual Growth Rate (%) 12.3 12.1 13.3 12.0 12.2 12.8 13.9 12.9 11.9 11.1 7.7CAGR (%, 2013-2018 and 2018-2024)

12.4 11.7

CAGR (%, 2013-2024) 12.0 Source: visiongain 2014



Table 6.18 and Figure 6.19 show visiongain’s estimates of Nasacort sales by volume over 2013-

2024.

Table 6.18 Sanofi: Nasacort Sales Forecast by Volume: Sprays (million), AGR (%), CAGR (%), 2013-2024

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024Nasacort (million sprays) 2.1 6.3 8.9 11.5 13.8 12.7 12.1 11.7 11.6 12.1 12.6 13.1

Annual Growth Rate (%) 206.6 40.0 30.0 20.0 -8.0 -5.0 -3.0 -1.0 4.0 4.0 4.0CAGR (%, 2013-2018 and 2018-2024)

43.9 0.4

CAGR (%, 2013-2024) 18.3

Figure 6.19 Sanofi: Nasacort Sales Forecast by Volume: Sprays (million), AGR (%), 2013-2024

6.14 QNasl (beclometasone, Teva)

QNasl (beclometasone dipropionate, Teva) is a new formulation of beclometasone approved by

the FDA in 2012. It is described as a “dry” nasal aerosol with a HFA propellant, as opposed to

aqueous nasal sprays, and is the first such dry spray to reach the US market for allergic rhinitis.

There is an unmet need for these types of spray due to the inconvenience of aqueous sprays: in

2010 the National Allergy Survey Assessing Limitations (NASAL) survey found that 1 in 5 patients

-50.0

0.0

50.0

100.0

150.0

200.0

250.0

0.0

2.0

4.0

6.0

8.0

10.0

12.0

14.0

16.0

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

AGR

(%)

Volu

me

(mill

ion

spra

ys)

Year Volume (million sprays)AGR (%)

Source: visiongain 2014




7.8.1 Patanase: Sales Forecast 2014-2024

Visiongain estimates that in 2013, Patanase revenues reached $41m, little changed from 2012

revenues of $40m. Sales will grow 3.3% to $43m in 2014. Visiongain believes that growth will be

slow during the forecast period, based on historical sales trends, and will reflect increasing demand

for allergic rhinitis drugs offset by the fact that many alternatives are available, including generic

azelastine. Visiongain predicts that Patanase revenues will grow with a CAGR of 3.9% over 2013-

2018 to reach $50m in 2018. Due to patent expiration in 2023 and falling revenues thereafter,

Patanase revenues will decline at a CAGR of -4.4% over 2018-2024 to reach $38m in 2024,

representing an overall CAGR of -0.7% over 2013-2024.

Table 7.5 and Figure 7.7 show visiongain’s estimates of Patanase revenues over 2013-2024.

Table 7.5 Novartis: Patanase Revenue ($m), AGR (%), CAGR (%), 2013-2024

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024Patanase ($m) 41 43 44 46 48 50 52 55 57 60 63 38 Annual Growth Rate (%) 3.3 3.7 4.0 4.2 4.4 4.6 4.8 5.0 5.1 5.1 -40.0CAGR (%, 2013-2018 and 2018-2024)

3.9 -4.4

CAGR (%, 2013-2024) -0.7

Figure 7.7 Novartis: Patanase Revenue ($m), AGR (%), 2013-2024

-45.0-40.0-35.0-30.0-25.0-20.0-15.0-10.0-5.00.05.010.0

0

10

20

30

40

50

60

70

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

AGR

(%)

Sale

s ($

m)

Year Sales ($m) AGR (%)





Astepro 0.15%. They do work. In terms of compliance one spray versus two has advantages.

Currently Dymista has a unique market space.

12.3.4 Trends and Developments in Allergic Rhinitis

visiongain: Are there any other trends or developments in the intranasal allergic rhinitis drugs

market?

Jonathan Bernstein: QNasl, the HFA [hydrofluoroalkane] aerosol, has a new mode of delivery. In

terms of novel compounds there are things in early stages of development that are being looked at

but they haven’t generated data in significant patient populations as of yet. Other novel agents

include intranasal CO2 and intranasal capsaicin which is over the counter and has effects on

reducing congestion. For allergic rhinitis, sublingual immunotherapies have been looked at. There

aren’t many novel nasal spray treatments under development at the moment.

12.4 Interview with Tonya Winders, President and CEO, Allergy &

Asthma Network Mothers of Asthmatics, Virginia, US

In March 2014 visiongain interviewed Tonya Winders, President and CEO of the Allergy and

Asthma Network Mothers of Asthmatics (AANMA). AANMA is the leading nonprofit family health

organisation in the US focusing on asthma, allergies and related conditions. We appreciate Tonya

Winders’ time and opinions.


visiongain: Can you tell me a little bit about the work that AANMA is doing in the area of allergic

rhinitis?

Tonya Winders: Allergy & Asthma Network Mothers of Asthmatics was founded in 1985 to "end

the needless death and suffering due to asthma, allergies and related conditions through outreach,

education and advocacy." The network is comprised of patients, caregivers and healthcare

professionals dedicated to this mission. We provide training and educational materials for allergic

rhinitis to millions of patients and caregivers each year.

Many people believe allergic rhinitis is just “hay fever” or a mild nuisance to sufferers. In reality, it

has a dramatic impact on a person’s quality of life including missed days at work and school or

“presenteeism” – showing up but not being as productive as normal. The high direct and indirect